Editas Medicine

EDITPhase 2

Cambridge, United StatesFounded 2013editasmedicine.com

Editas Medicine is a leader in the CRISPR gene editing space, aiming to discover, develop, manufacture, and commercialize a robust pipeline of genomic medicines. The company leverages two distinct CRISPR nucleases, Cas9 and Cas12a, to access a broad range of genetic mutations and develop targeted in vivo therapies. Its strategic focus includes hemoglobinopathies, in vivo editing of hematopoietic stem cells and liver, and advancing cellular therapy assets through key partnerships with Bristol-Myers Squibb and Immatics N.V.

Market Cap

$229.0M

Founded

2013

EDIT · Stock Price

USD 2.3416.42 (-87.53%)

Historical price data

AI Company Overview

Technology Platform

Dual CRISPR nuclease platform utilizing both Cas9 and Cas12a (Cpf1) for in vivo gene editing, enabling a broad range of DNA targeting and repair strategies for developing transformative genomic medicines.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage	Watch
EDIT-101	Leber Congenital Amaurosis 10	Phase 1/2

Opportunities

The primary growth opportunity is the clinical validation and commercialization of EDIT-401 for hyperlipidemia, a massive prevalent disease.

Success would open the door to applying its in vivo platform to other common chronic conditions.

Further opportunities lie in advancing its hemoglobinopathy programs and leveraging its partnerships in oncology cell therapy.

Risk Factors

Key risks include clinical failure of lead assets, particularly EDIT-401 in human trials; intense competition from other gene editing biotechs; the high cost and complexity of manufacturing in vivo therapies; dependence on future capital raises; and navigating the evolving CRISPR IP landscape.

Competitive Landscape

Editas faces direct competition from Intellia Therapeutics (in vivo editing), Verve Therapeutics (cardiovascular base editing), and CRISPR Therapeutics/Vertex (hemoglobinopathies). Its differentiation lies in its dual nuclease platform and its specific focus on gene upregulation strategies for in vivo applications.